---
document_datetime: 2025-09-04 13:44:02
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/skyclarys-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: skyclarys-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5159063
conversion_datetime: 2025-12-20 13:06:04.772525
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Skyclarys

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                               | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|-------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | B.II.b.2.cReplacementor additionofa | 03/09/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000294883                        | manufacturerresponsibleforimportation and/or batch release - B.1I1.b.2.c.1 Not includingbatchcontrol/testing-Accepted                                                        |            |     | PL   |                   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-------------------|
| Variation type IB /                      | C.IHUMANANDVETERINARYMEDICINAL PRODUCTS-C.I.z Other variation-Accepted                                                                                                       | 24/07/2025 | N/A |      | EMA/VR/0000276345 |
| Variation type IA_IN / EMA/VR/0000275830 | B.II.b.1Replacementor addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.I1.b.1.a Secondary packaging site - Accepted | 03/06/2025 | N/A |      |                   |
| Variation type IA /                      | A.ADMINISTRATIVE CHANGES -A.6 Change inATCCode/ATCVetCode-Accepted                                                                                                           | 03/03/2025 | N/A | SmPC | EMA/VR/0000256186 |